Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10% and 0.13%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Amicus is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The Company anticipates continuing to grow its current commercial ...
Amicus (FOLD) is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The ...
The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.
Besides Wall Street's top -and-bottom-line estimates for Amicus Therapeutics (FOLD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...
The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...
Life sciences trade association BioNJ has announced the election of its 2025 Officers and Board Members in concert with BioNJ ...
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...
Hosted on MSN7d
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseWall Street expects a year-over-year increase in earnings on higher revenues when Amicus Therapeutics (FOLD) reports results for the quarter ended December 2024. While this widely-known consensus ...
The government’s decision to reject the two names recommended by Amicus Curiae Adv Nigel de Costa Frias on the Noise Monitori ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback